跳至主要内容
临床试验/CTRI/2025/08/093806
CTRI/2025/08/093806尚未招募2 期

A Randomized Comparative Clinical Study to Evaluate the Efficacy of JatyadiGhrita and Kampillakadi Taila Suppositories in the Management of Acute Fissure-in-Ano.

Institute for Ayurved Studies & Research Shri Krishna AYUSH University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2025年10月10日最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
60
试验地点
1
主要终点
Reduction in pain during defecation (Visual Analogue Scale score)

研究概览

简要总结

In this Randomized Comparative Clinical study, 60 patients with fissure in Ano (Guda Vidaran) will be enrolled after meeting the necessary criteria and informed consent. In Group A, 30 patients would be treated with Jatyadi Ghrita Suppositories, prepared by mixing jatyadi ghrit with cocoa butter in it, given as a Daily dose of 1 suppository per anal after the defecation, And in Group B would also have 30 patients, who would receive Kampillakadi Taila Suppositories prepared by the same method as Jatyadi ghrita suppositories, with the same dose of medication and intervals. Before starting the treatment, all patients would be tested for essential investigation to ensure they meet the study’s requirements and informed consent will be taken.

The effectiveness of the treatments will be measured by Pain Assessment Criteria in VAS readings from 1 to 10 by questionnaire. After the treatments, the results will be analyzed statistically

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
20.00 Year(s) 至 40.00 Year(s)(—)
性别
All

入选标准

  • Symptoms of pain during defecation, bleeding per rectum, and visible linear ulcer, between Age group of 20-40 years, of either gender.
  • Patients willing to undergo trial.

排除标准

  • Age: below 20 years or above 40 years | Sex: both male and female] Patients who are diagnosed with conditions such as anal fistula, anorectal abscess, or Grade III–IV haemorrhoids will be excluded from the study.
  • Individuals with immunosuppressive or systemic disorders, including Type 2 Diabetes Mellitus, HIV infection, Syphilis, Hepatitis B, Hepatitis C, Tuberculosis, or Crohn’s disease, will not be considered eligible.
  • Patients with a history of anorectal or other malignancies, as well as pregnant or lactating women, will also be excluded.
  • Furthermore, any patient deemed unsuitable for the investigational drug or with a known hypersensitivity or adverse reaction to the drug will not be included in the trial.

结局指标

主要结局

Reduction in pain during defecation (Visual Analogue Scale score)

时间窗: 1st- 0 Day | 2nd- After completion of Trial | 3rd- 1 Month after completion of follow up after trial

次要结局

  • 1, Reduction in bleeding per rectum.(2, Improvement in local inflammation signs (Tenderness).)

研究者

发起方
Institute for Ayurved Studies & Research Shri Krishna AYUSH University
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Bittu

Institute For Ayurved Studies and Research Shri Krishna AYUSH University

研究点 (1)

Loading locations...

相似试验